IPIC 2023

Octapharma Symposium

Share this page


Clinical cases: Uncovering atypical manifestations of PID

Friday, 10 November 2023
13:45 - 14:45 CET
Room: Rotterdam Hall

Classical immunodeficiencies are mainly characterized by infectious conditions. Although in the recent years manifestations related to allergy, inflammation, autoimmunity, lymphoproliferation, and malignancies have been described, it can be difficult to unravel the relationship between primary immunodeficiencies (PID), secondary immunodeficiencies (SID) and hematological malignancy or autoimmunity in the clinical setting.

During this session, the audience will actively participate in the discussion around interactive clinical cases showcasing atypical manifestations of PID with various clinical presentations.

Symposium programme



Welcome and introduction

Chair: Elie Haddad (Montreal, Canada)

Case 1: Unmasking PID in a SID patient with haematological malignancy

Stephen Jolles (Cardiff, UK)

Case 2: A surprising diagnosis

Elie Haddad (Montreal, Canada)

Case 3: Could neuropsychiatric disorders PANS/PANDAS be associated with PID?

Michael Daines (Tucson, Arizona, USA)

Closing Remarks

Elie Haddad (Montreal, Canada)

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.

Meet the speakers

Chair: Elie Haddad

Sainte-Justine University Hospital, Montreal, Canada

Stephen Jolles

University Hospital of Wales, Cardiff, UK

Michael Daines

University of Arizona, Tucson, USA

To attend this symposium, register to the IPIC 2023 congress.

Visit event page on Science Hub

Are you unable to attend this event? Visit Science Hub to access the session recording.

Learn more about SID

Visit our information hub for healthcare professionals to learn more about secondary immunodeficiencies and hematological malignancies.